[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:epo-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"EPO Gene",3,2,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04419649","A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)",[12],"Phase 2","RECRUITING","2026-08-26T02:15:54.846520Z","2026-05-05T02:43:29.043989Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07096297","Luspatercept + Darbepoetin in MDS",[12],"2026-08-26T02:18:09.641312Z","2026-05-05T02:43:28.971039Z",{"nct_id":23,"title":24,"phases":25,"status":27,"updated_at":28,"content_modified":29},"NCT05949684","ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions",[26],"Phase 3","ACTIVE_NOT_RECRUITING","2026-08-03T02:32:57.702658Z","2026-05-05T02:43:27.434976Z"]